A sonoelectric artificial meningeal device for enhanced implantable electric field ablation of glioblastoma
Open Access
- 23 June 2026
- journal article
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Abstract
Electric field tumor therapy has emerged as a promising non-invasive treatment for glioblastoma (GBM), but its clinical efficacy is severely limited by skull-induced attenuation of electric field intensity. To overcome this limitation, we developed a multilayer thin-film sonoelectric meningeal device (MF-SMD) consisting of an electrospun PLGA artificial meningeal scaffold integrated with a microneedle-based triboelectric film. This device converts externally applied low-intensity ultrasound into intracranial electric fields, enabling transcranial, localized, and controllable electric ablation of brain tumors. Upon low-intensity ultrasound excitation, the film generates localized intracranial electric fields that disrupt tumor mitosis while preserving neuronal integrity, and significantly reduce skull-induced field attenuation. In vitro and in vivo experiments validated the antitumor efficacy of the device, achieving approximately 68% proliferation inhibition in clinical GBM cell lines and a 72% reduction in tumor burden in orthotopic mouse models. Notably, compared with conventional tumor treating fields (TTF) systems that employ extracranial electrodes, the MF-SMD maintained electric field attenuation below 20% at therapeutic frequencies. These results establish a novel therapeutic paradigm that overcomes skull-induced electric field attenuation, addressing a key challenge in transcranial brain tumor therapy.Keywords
Funding Information
- Guangdong Provincial Key Laboratory of Sensor Technology and Biomedical Instrument (2020B1212060077)
- National Natural Science Foundation of China (32101160)
This publication has 14 references indexed in Scilit:
- Advancing glioblastoma therapy: Learning from the past and innovations for the futureCancer Letters, 2025
- Glioblastoma cells increase expression of notch signaling and synaptic genes within infiltrated brain tissueNature Communications, 2024
- Stemness, invasion, and immunosuppression modulation in recurrent glioblastoma using nanotherapyWIREs Nanomedicine and Nanobiotechnology, 2024
- Advancing glioblastoma treatment by targeting metabolismNeoplasia, 2024
- Glioblastoma and Other Primary Brain Malignancies in AdultsJAMA, 2023
- Skull defect increases the tumor treating fields strength without detrimental thermogenic effect: A computational simulating researchCancer Medicine, 2022
- Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasionCell, 2021
- Tumour treating fields therapy for glioblastoma: current advances and future directionsBritish Journal of Cancer, 2020
- Brain malignancies: Glioblastoma and brain metastasesSeminars in Cancer Biology, 2020
- Tumour cell teamworkNature Reviews Cancer, 2015